Researchers bioengineer algae to make high-value and affordable biologics products at commercial scale.
Washington-based Lumen Bioscience is the first biotech company to produce a range of high-value oral biologics by engineering Spirulina, a blue-green algae. These biologics cover antibody therapeutics and vaccines – both long time unmet needs in healthcare. Springwise has reported many algae-related innovations in the past. Examples include a wooden motorbike that runs on algae oil, and a ‘living chandelier’ that absorbs carbon dioxide from the air and releases oxygen.
Having pioneered a natural blue pigment to replace those made from petroleum last year, Lumen is aiming higher. Today, it seeks to harness the unique nutritional benefits of Spirulina in areas that have boggled traditional biotechnology platforms. ‘It’s hard to get plants or alginates to express protein at higher levels’, says Michael Tasch at Lumen’, ‘but we’ve cracked the code’.
In November, Lumen was issued a broad US patent for its novel set of gene editing tools and methods. The patent would allow researchers to integrate stably engineered forms of Spirulina into global health approaches. This means faster timelines for drug development and lower costs. It also means increased availability of cures for the hundreds of millions afflicted with disease each year.
Among other programs, Lumen received a grant from National Institutes of Health (NIH) to continue developing its low-cost, Spirulina-based oral malaria vaccine. Unlike injected vaccines, Lumen’s does not need refrigerated storage and distribution. In May, a grant was awarded by the US Department of Agriculture (USDA) to manufacture oral vaccines that protected farmed fish from IHNV. IHNV is fatal to salmonid fish like trout and salmon, and has costed millions in lost sales.